VEGF-D human

recombinant, expressed in HEK 293 cells, ≥95% (SDS-PAGE), ≥95% (HPLC), suitable for cell culture

Vascular Endothelial Growth Factor-D, FIGF
Pricing and availability is not currently available.

biological source



expressed in HEK 293 cells


≥95% (HPLC)
≥95% (SDS-PAGE)



mol wt

20.0-22.0 kDa


pkg of 10 μg


cell culture | mammalian: suitable


<0.1 EU/μg endotoxin, tested



UniProt accession no.

shipped in

wet ice

storage temp.


Gene Information

human ... FIGF(2277)

General description

VEGFD (vascular endothelial growth factor D), or c-fos-induced growth factor, is a member of the VEGF family of growth factors, and is composed of VEGF-homology domain, receptor binding domains, and pro-peptides in both terminals. It is secreted in the extracellular space in a full length form with both C- and N-terminal pro-peptides, which are cleaved off to produce the mature VEGFD form. It is an angiogenesis-related factor.
Recombinant human VEGF-D is a 26.2 kDa non-disulfide linked homodimeric protein consisting of two 117 amino acid polypeptide chains. Due to glycosylation the protein migrates as a 20.0-22.0 kDa band under non-reducing condition.


VEGFD (vascular endothelial growth factor D) human has been used in for the treatment of buffalo luteal cell culture to determine the effect of VEGFD on the expression of lymphatic endothelial marker (LYVE1), thereby investigating the role of VEGFD in luteal lymphangeogenesis during different stages of estrous cycle.

Biochem/physiol Actions

Mature VEGFD (vascular endothelial growth factor D) interacts with VEGFR-3, a tyrosine kinase receptor, with high affinity. This receptor predominantly resides on adult lymphatic endothelium and participates in lymphangiogenesis. VEGFD also interacts with Nrp-2 (neuropilin), a non-tyrosine kinase receptor, which functions as a lymphangiogenesis-associated factor. This factor promotes tumor lymphangiogenesis and hence, lymph node metastasis in various cancers, such as ovarian cancer. In patients with CRC (colorectal cancer), higher expression of VEGFD is linked with resistance to bevacizumab, and has potential as a biomarker for predicting the benefit of bevacizumab in CRC chemotherapy.



Physical form

Lyophilized with no additives.


Centrifuge the vial prior to opening. Reconstitute in water to a concentration of 0.1-1.0 mg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 week. For extended storage, it is recommended to further dilute in a buffer containing a carrier protein (example 0.1% BSA) and store in working aliquots at -20°C to -80°C.


NONH for all modes of transport

WGK Germany


Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificate of Analysis
Certificate of Origin
Expression and localization of locally produced growth factors regulating lymphangiogenesis during different stages of the estrous cycle in corpus luteum of buffalo (Bubalus bubalis).
Ali I et al
Theriogenology, 81(3), 428-436 (2014)
VEGF-D-induced draining lymphatic enlargement and tumor lymphangiogenesis promote lymph node metastasis in a xenograft model of ovarian carcinoma.
Du LC et al
Reproductive Biology and Endocrinology, 12, 14-14 (2014)
Daniela C García et al.
Zygote (Cambridge, England), 26(3), 242-249 (2018-06-09)
SummaryThe mammalian oviduct plays a pivotal role in the success of early reproductive events. The urokinase plasminogen activator system (uPAS) is present in the bovine oviduct and is involved in extracellular matrix remodelling through plasmin generation. This system can be...
Ellen C Breen
Journal of cellular biochemistry, 102(6), 1358-1367 (2007-11-06)
Vascular endothelial growth factor A (VEGF-A) belongs to a family of heparin binding growth factors that include VEGF-B, VEGF-C, VEGF-D, and placental-like growth factor (PLGF). First discovered for its ability to regulate vascular endothelial cell permeability, VEGF is a well-known...
Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer.
Weickhardt AJ et al
British Journal of Cancer, 113(1), 37-45 (2015)

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon


Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.